San Juan Capistrano, CA, United States of America

Hampar L Karageozian

This inventor holds 24 USPTO granted patents and 15 published patent applications and 3 EPO patents, primarily in Ophthalmic Treatments. Top assignees: S.k. Pharmaceuticals, Inc., Ista Pharmaceuticals, Inc., Advanced Corneal Systems. Active years: 1979-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hampar L Karageozian. Retrieved from https://idiyas.com/inventor/hampar-l-karageozian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 

% Patents Active = 75.0

 

Average Co-Inventor Count = 2.0

ph-index = 10

Forward Citations = 410(Granted Patents)


Location History:

  • Laguna Hills, CA (US) (1979)
  • San Juan Capistrano, CA (US) (1997 - 2023)

Company Filing History:


Years Active: 1979-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Oxidative Stress
Peptide Therapies
Cancer Treatment
Chlorite Antimicrobials
Integrin Receptor Antagonists
Glycosaminoglycan Preparations
Optic Nerve Implants
Intraocular Pressure
Hyaluronidase
Corneal Scars
Enzyme-Orthokeratology
Radioactive Technetium-99M
24 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Hampar L. Karageozian

Introduction

Hampar L. Karageozian, based in San Juan Capistrano, California, has made significant contributions to the field of pharmaceuticals, particularly in peptide therapies and their applications. With an impressive portfolio of 23 patents, he continues to push the boundaries of innovation in medical science.

Latest Patents

Among his latest endeavors, Karageozian has developed groundbreaking peptide therapies aimed at the reduction of macular thickening. His patents encompass compounds comprising R-G-Cysteic Acid, including its derivatives such as Arg-Gly-NH—CH(CH—SOH)COOH. These compounds, which include pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, and pro-drugs, hold promise for various therapeutic applications. The methods he has disclosed involve inhibiting integrins like αβ-Integrin and addressing cellular adhesion to RGD binding sites, thereby preventing or treating viral or microbial infections and inhibiting angiogenesis in tumors and retinal tissues.

Additionally, Karageozian has outlined peptides that can aid in treating cancer, again focusing on the same foundational compounds and their derivatives. The innovations here also address methods for mitigating issues related to integrin functionalities and enhancing the delivery of diagnostic and therapeutic agents.

Career Highlights

Karageozian's extensive career includes key positions in several pioneering pharmaceutical companies. Notably, he has worked with S.K. Pharmaceuticals, Inc. and Ista Pharmaceuticals, Inc., where he has played an instrumental role in developing innovative therapeutic solutions.

Collaborations

Throughout his career, collaboration has been a vital aspect of Karageozian’s success. He has closely worked with other experts in the field, including notable colleagues like Vicken H. Karageozian and John Y. Park. These collaborations have not only enriched his work but have also fostered advancements in the pharmaceutical sciences.

Conclusion

Hampar L. Karageozian exemplifies the spirit of innovation within the pharmaceutical industry. With a dedicated focus on peptide therapies and their applications in treating various medical conditions, he continues to make substantial contributions to the field. His patents and collaborations reflect a commitment to advancing science and improving patient outcomes, underscoring his role as a prominent inventor in the realm of medical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…